Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lytix Biopharma AS ( (DE:6BG) ) has issued an announcement.
Lytix Biopharma AS has decided against proceeding with a proposed subsequent share offering after successfully raising NOK 111.3 million through a private placement and a retail offering. The decision was influenced by the company’s stock trading around the subscription price, allowing existing shareholders to mitigate dilution effects, and reflecting positively on the company’s financial strategy and market conditions.
More about Lytix Biopharma AS
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company specializing in host-defense peptide-derived molecules for cancer treatment. Their lead product, LTX-315, is an innovative oncolytic molecule designed to enhance anti-cancer immunity. Lytix has a pipeline that addresses various cancer indications, offering both mono and combination therapies.
YTD Price Performance: -0.21%
Average Trading Volume: 2,166
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €33.92M
For an in-depth examination of 6BG stock, go to TipRanks’ Stock Analysis page.